With reference to letter dated 27th January 2022, Transgene Biotek has informed that at the meeting of the Board of Directors of the Company held on 14th February 2022 the following decisions have been taken: Approved the Unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Company for the quarter ended 31st December 2021 and approved the Licensing agreement between Transgene Biotek (the company) and NiedlFree Technologies.
The above information is a part of company’s filings submitted to BSE.
